Physician profile
Esha Sachdev
NPI 1114260460
$5,439.50
in general payments reported to CMS, 2019-2025
43 companies · $667 in 2025
The $667 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2021: $124 · 2022: $733 · 2023: $2,317 · 2024: $1,403 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821 · Consulting Fee: $1,260 · Education: $284 · Travel and Lodging: $22.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.21 |
| Consulting Fee | $1,260.00 |
| Education | $283.97 |
| Travel and Lodging | $22.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,346.44 | 2023-2024 | Rybrevant, Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $344.70 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $326.22 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $296.05 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $240.58 | 2022-2025 | Enhertu |
| Abbvie INC. | $216.29 | 2023-2025 | Venclexta |
| Pfizer INC. | $206.58 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $181.54 | 2023-2025 | Enhertu, Tagrisso |
| Takeda Pharmaceuticals U.S.A., INC. | $175.71 | 2023-2024 | Ninlaro, Fruzaqla |
| Gilead Sciences, INC. | $165.56 | 2022-2025 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $160.50 | 2022-2024 | Ultomiris |
| Eisai INC. | $128.45 | 2022-2024 | |
| Incyte Corporation | $128.04 | 2022-2023 | |
| Novo Nordisk INC | $124.19 | 2021 | |
| Beigene USA, INC. | $123.40 | 2022-2024 | Brukinsa |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $121.90 | 2019 | |
| Emd Serono, INC. | $100.94 | 2023-2024 | Bavencio |
| Puma Biotechnology, INC. | $98.12 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $88.09 | 2019-2024 | Opdualag, Opdivo |
| Glaxosmithkline, LLC. | $75.06 | 2022-2024 | Zejula, Jemperli, Ojjaara |
| Karyopharm Therapeutics INC. | $68.39 | 2022-2024 | Xpovio |
| Stemline Therapeutics INC. | $55.05 | 2023-2024 | Orserdu |
| Sumitomo Pharma America, INC. | $52.70 | 2024-2025 | Orgovyx |
| Lilly USA, LLC | $52.40 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $50.74 | 2022 | |
| Sobi, INC | $49.45 | 2022-2024 | |
| Amgen INC. | $45.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.51 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $39.99 | 2022-2023 | Imbruvica |
| Seagen INC. | $39.82 | 2022-2023 | Tukysa |
| Aveo Pharmaceuticals, INC. | $35.42 | 2024 | |
| Rigel Pharmaceuticals, INC. | $29.69 | 2022 | |
| Taiho Oncology, INC. | $28.81 | 2022 | |
| Sun Pharmaceutical Industries INC. | $24.91 | 2024 | |
| Genentech USA, INC. | $24.90 | 2023 | Tecentriq |
| Astellas Pharma US INC | $21.84 | 2022 | |
| Adc Therapeutics America, INC. | $21.67 | 2023 | |
| Caris Mpi, INC. | $20.07 | 2025 | Mi Cancer Seek |
| Foundation Medicine, INC. | $18.97 | 2023 | Foundationone Liquid Cdx |
| Array Biopharma INC | $18.75 | 2024 | Lorbrena, Mektovi, Braftovi |
| Chiesi USA, INC. | $17.44 | 2023 | Ferriprox |
| Morphosys, US INC. | $16.21 | 2022 | |
| Emmaus Medical, INC. | $15.99 | 2023 | Endari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esha Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.